This bill is designed to keep FDA-regulated specialized infant formula available for premature babies who need it. It would primarily affect infants with medical nutrition needs, their parents, neonatal intensive care units, hospitals, and the manufacturers that produce these specialized formulas. The core policy goal is to reduce the risk of shortages or disruptions in a product category that can be critical for preterm infants’ growth and recovery.
What This Bill Does
- Aims to ensure the continued availability of specialized infant formula.
- Applies to formula regulated by the Food and Drug Administration.
- Targets formulas used for preterm babies with special nutritional needs.
- Seeks to reduce supply disruptions for hospitals and families.
- Addresses access to a medically important infant nutrition product.
Who This Bill Affects
If you are the parent or caregiver of a preterm baby, or you work in neonatal care, this bill could improve access to the specialized FDA-regulated formula those infants often need. That can reduce the risk of shortages, emergency substitutions, and the added costs of finding medically appropriate formula. For most other people, the bill has little direct day-to-day effect.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Parents of premature infants They want dependable access to the specific formula their babies need. Even short disruptions can create immediate health risks, costly substitutions, and major stress during an already difficult time.
- Neonatal doctors and hospital nutrition teams They need a stable supply of medically appropriate formula to support fragile newborns. Consistent availability helps them follow treatment plans and avoid delays in care.
- Infant formula manufacturers Clear federal attention to specialized formula can support a more stable market and better planning for production and distribution. That can reduce panic-driven shortages and improve confidence in supply chains.
- Small formula distributors and importers Additional federal requirements or market expectations could increase compliance burdens and make it harder to source or move specialized products quickly. Smaller firms may worry about narrower margins in an already sensitive market.
- Free-market supply chain advocates They may argue the bill could encourage government involvement in a product market that should respond to consumer demand and private contracting. They may prefer incentives for competition and production rather than a federal protection framework.
- Budget watchdogs Any new federal monitoring, enforcement, or related administrative activity could add costs, even if the bill is targeted. They may question whether those expenses are justified relative to the size of the affected population.
Key Implications
-
““continued availability of specialized infant formula””
This signals a focus on keeping a medically necessary product on shelves and in hospital supply chains, rather than treating formula as an ordinary consumer good. Families with preterm infants would be the main beneficiaries of fewer interruptions.
-
““regulated by the Food and Drug Administration””
The bill is aimed at formula already within FDA oversight, which means the policy operates through federal food and drug rules rather than a separate state-level program. That can matter for nationwide consistency in product standards and supply.
-
““for preterm babies””
The intended beneficiaries are a narrow medical group: infants born before full term. The practical effect is concentrated in NICUs, pediatric care settings, and households managing high-risk newborn feeding needs.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- S 4940
- Congress
- 119th Congress
- Official title
- A bill to ensure the continued availability of specialized infant formula regulated by the Food and Drug Administration for preterm babies.
- Policy area
- Healthcare
- Latest action
- Read twice and referred to the Committee on the Judiciary. (June 24, 2026)
- Last updated
- June 25, 2026
Latest Status
June 24, 2026
Read twice and referred to the Committee on the Judiciary.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.